Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.
Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...
10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Alongside the amended certificate, Metsera, Inc. also updated its bylaws.
20d
GlobalData on MSNGLP-1RA developer Metsera targets $289m IPOMetsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...
Drugs that activate the GLP-1 receptor transformed the treatment of obesity, but biotech company Metsera contends that limitations keep them from expanding their reach. The weekly injections and ...
A Quick Take On Metsera, Inc. Metsera, Inc. (NASDAQ:MTSR) has filed to raise $275 million in an IPO of its common stock, according to SEC S-1/A registration information. The firm is a clinical ...
Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Metsera (NASDAQ:MTSR) shares opened at $25 ...
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated ...
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...
Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results